The use of Acarbose in Type 2 diabetic patients in secondary failure: Effects on glycaemic control and diet induced thermogenesis

Diabetes Research and Clinical Practice

Volumn 42, Issue 3, 1998, Pages 175-180

  Brooks, B ^a,b   Molyneaux, L ^a   Zilkens, R ^a   Ross, G ^a   Yue, D K ^a,b  

^a Diabetes Centre   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Complications; Fat oxidation; Hyperglycaemia; Oral agents; Thermogenesis

Indexed keywords

ACARBOSE; BIGUANIDE; CARBOHYDRATE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SUCROSE; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CALORIMETRY; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DRUG ACTIVITY; ENERGY EXPENDITURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RESPIRATORY QUOTIENT; THERMOGENESIS; TREATMENT FAILURE; TREATMENT INDICATION;

ACARBOSE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY TEMPERATURE REGULATION; DIABETES MELLITUS, TYPE 2; EATING; ENERGY METABOLISM; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REGRESSION ANALYSIS; RESPIRATION; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE; TRIGLYCERIDES; TRISACCHARIDES;

EID: 0032417856     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00114-4     Document Type: Article

References (10)

1. Balfour J.A., McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 46:1993;1025-1054.
2. (Consenus Statement), The pharmacological treatment of hyperglycaemia in NIDDM, Diabetes Care 19, (Suppl. 1) (1996) S54-S61.
3. Balfour J.A., Wilde M.I. Management of Type 2 diabetes: defining the role of Acarbose. Dis. Manag. Health Outcomes. 2:1997;248-260.
4. DCCT Research Group, The effect of intensive treatment of diabetes on the devleopment and progression of long-term complications in insulin-dependent diabetes mellitus, New Engl. J. Med. 329, (1993) 977-986.
5. United Kingdom Prospective Diabetes Study Group, United Kingdom prospective diabetes study (UKPDS): relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non insulin dependent diabetes mellitus followed for 3 years, Br. Med. J. 310, (1995) 83-88.
6. Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 year study. Diabet. Res. Clin. Pract. 28:1995;103-117.
7. The Diabetes Control and Complications Trial Research Group, The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial, Diabetes 45, (1995) 1289-1298.
8. Viberti G. A glycemic threshold for diabetic complications? New Engl. J. Med. 332:1995;1293-1294.
9. Krolewski A.S., Laffel L.M.B., Krolewski M., Quyinn M., Warram J.H. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin dependent diabetes mellitus. New Engl. J. Med. 332:1995;1251-1255.
10. M. Toeller, Inhibiteurs de l'alpha-glucosidase. In: Journes de diabetologie de l'Hotel-Dieu. Flammarion Medicine-Sciences, Paris, 199l, pp. 203-212.